The Independent Data Monitoring Committee recommended transitioning patients in the placebo arm to garetosmab as soon as possible. Topline data were announced from a phase 3 trial evaluating ...

BELLMAWR, New Jersey (WPVI) -- A young South Jersey boy has one wish for his birthday this year, and that is to help raise money for those living with a rare disease. Nine-year-old AJ Gonzales of ...

FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab is the first and only treatment to demonstrate a dramatic ...

Fibrodysplasia ossificans progressiva is a rare and life-threatening genetic disease caused by gain-of-function mutations in the ALK2 gene, which encodes activin receptor-like kinase 2. Blueprint ...

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the Health Canada approval of Sohonos (palovarotene capsules), an oral selective retinoic-acid receptor gamma ...

The U.S. Food and Drug Administration (FDA) recently approved palovarotene (Sohonos) as the first treatment for fibrodysplasia ossifcans progressiva (FOP), a severely disabling condition that causes ...

There are plenty of companies chasing the first U.S. FDA-approved treatment for the ultra-rare disease fibrodysplasia ossificans progressiva (FOP), but Ipsen SA stayed the course longer and won that ...

PARIS, FRANCE, 16 August 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today approval by the U.S. Food and Drug Administration (FDA) of Sohonos™ (palovarotene) capsules as a retinoid indicated ...